Based on this result, in 2019, China’s National Medical Products Administration (NMPA) formally approved nivolumab as the first immunosuppressant in China to treat patients with PD-L1-positive head and neck squamous cell carcinoma during or after platinum-containing regimens. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.